Splenic marginal zone lymphoma natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
[[Hemoglobin]] level of less than 12 g/dL, [[lactate dehydrogenase]] level higher than normal, blood serum [[albumin]] levels of less than 3.5 g/dL,  and  some genetic mutations, such as mutations in ''NOTCH2'' are associated with a particularly poor prognosis among patients with splenic marginal zone lymphoma.
[[Hemoglobin]] level of less than 12 g/dL, [[lactate dehydrogenase]] level higher than normal, blood serum [[albumin]] levels of less than 3.5 g/dL,  and  some genetic mutations, such as mutations in ''NOTCH2'' are associated with a particularly poor prognosis among patients with splenic marginal zone lymphoma.
==Prognosis==
==Prognosis==
* Poor prognosis criteria <ref name="Arcaini2006">{{cite journal|last=Arcaini|first=L.|year=2006|title=Splenic marginal zone lymphoma: a prognostic model for clinical use|journal=Blood|volume=107|issue=12|pages=4643–4649|issn=0006-4971|doi=10.1182/blood-2005-11-4659}}</ref>
* Poor prognosis criteria for splenic marginal zone lymphoma include: <ref name="Arcaini2006">{{cite journal|last=Arcaini|first=L.|year=2006|title=Splenic marginal zone lymphoma: a prognostic model for clinical use|journal=Blood|volume=107|issue=12|pages=4643–4649|issn=0006-4971|doi=10.1182/blood-2005-11-4659}}</ref>
:* [[Hemoglobin]] level of less than 12 g/dL
:* [[Hemoglobin]] level of less than 12 g/dL
:* [[Lactate dehydrogenase]] level higher than normal
:* [[Lactate dehydrogenase]] level higher than normal

Revision as of 16:50, 14 January 2016

Splenic marginal zone lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Splenic marginal zone lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Splenic marginal zone lymphoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Splenic marginal zone lymphoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Splenic marginal zone lymphoma natural history, complications and prognosis

CDC on Splenic marginal zone lymphoma natural history, complications and prognosis

Splenic marginal zone lymphoma natural history, complications and prognosis in the news

Blogs on Splenic marginal zone lymphoma natural history, complications and prognosis

Directions to Hospitals Treating Splenic marginal zone lymphoma

Risk calculators and risk factors for Splenic marginal zone lymphoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Hemoglobin level of less than 12 g/dL, lactate dehydrogenase level higher than normal, blood serum albumin levels of less than 3.5 g/dL, and some genetic mutations, such as mutations in NOTCH2 are associated with a particularly poor prognosis among patients with splenic marginal zone lymphoma.

Prognosis

  • Poor prognosis criteria for splenic marginal zone lymphoma include: [1]
  • Hemoglobin level of less than 12 g/dL
  • Lactate dehydrogenase level higher than normal
  • Blood serum albumin levels of less than 3.5 g/dL
  • Some genetic mutations, such as mutations in NOTCH2, are also correlated with shorter survival

References

  1. Arcaini, L. (2006). "Splenic marginal zone lymphoma: a prognostic model for clinical use". Blood. 107 (12): 4643–4649. doi:10.1182/blood-2005-11-4659. ISSN 0006-4971.

Template:WH Template:WS